TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07007559: ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Sponsor: ALX Oncology Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT07007559 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07007559 Rescue Dossier →